Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile

BACKGROUND: Recurrent Clostridium difficile infections (rCDI) are associated with decreased diversity and altered intestinal microbiome compared with healthy patients. RBX2660, a standardized microbiota-based drug, is designed to restore microbiome diversity and composition in patients’. The effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Sahil, Blount, Ken, Jones, Courtney, Shannon, Bill, Carter, Sharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630729/
http://dx.doi.org/10.1093/ofid/ofx163.963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630729/
http://dx.doi.org/10.1093/ofid/ofx163.963

Ejemplares similares